Gopal Sapparapu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2236465/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Science Immunology, 2019, 4, .	11.9	147
2	A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions. Nature Microbiology, 2019, 4, 71-77.	13.3	25
3	Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling. Journal of Clinical Investigation, 2019, 130, 315-328.	8.2	11
4	Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus. MBio, 2018, 9, .	4.1	32
5	Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth. PLoS ONE, 2018, 13, e0209437.	2.5	8
6	Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region. Nature Microbiology, 2018, 3, 670-677.	13.3	68
7	A human antibody against Zika virus crosslinks the E protein to prevent infection. Nature Communications, 2017, 8, 14722.	12.8	122
8	Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination. Journal of Virology, 2017, 91, .	3.4	44
9	Monoclonal Antibodies Against the Staphylococcus aureus Bicomponent Leukotoxin AB Isolated Following Invasive Human Infection Reveal Diverse Binding and Modes of Action. Journal of Infectious Diseases, 2017, 215, 1124-1131.	4.0	65
10	Human Monoclonal Antibodies to the Staphylococcus aureus Toxin LukAB have Distinct Mechanisms of Protection and Are Efficacious In Vivo. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
11	Determinants of VH1-46 Cross-Reactivity to Pemphigus Vulgaris Autoantigen Desmoglein 3 and Rotavirus Antigen VP6. Journal of Immunology, 2016, 197, 1065-1073.	0.8	21
12	Long antibody HCDR3s from HIV-naÃ ⁻ ve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4446-4451.	7.1	20
13	Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody. Proceedings of the United States of America, 2016, 113, E5830-E5837.	7.1	41
14	Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature, 2016, 540, 443-447.	27.8	349
15	Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. Cell, 2016, 167, 684-694.e9.	28.9	141
16	Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Cell, 2016, 164, 392-405.	28.9	160
17	Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site. Journal of Virology, 2016, 90, 780-789.	3.4	50
18	Recognition of influenza H3N2 variant virus by human neutralizing antibodies. JCI Insight, 2016, 1, .	5.0	20

GOPAL SAPPARAPU

#	Article	IF	CITATIONS
19	H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. Journal of Clinical Investigation, 2016, 126, 1482-1494.	8.2	62
20	Frequent Use of the IgA Isotype in Human B Cells Encoding Potent Norovirus-Specific Monoclonal Antibodies That Block HBGA Binding. PLoS Pathogens, 2016, 12, e1005719.	4.7	27
21	Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus. Cell, 2015, 160, 893-903.	28.9	130
22	Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Cell Host and Microbe, 2015, 18, 86-95.	11.0	116
23	Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9346-9351.	7.1	26
24	Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13898-13903.	7.1	50
25	Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. Journal of Clinical Investigation, 2015, 125, 2523-2531.	8.2	31
26	Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen. Aids, 2014, 28, 2201-2211.	2.2	4
27	Intracellular neutralization of a virus using a cell-penetrating molecular transporter. Nanomedicine, 2014, 9, 1613-1624.	3.3	7
28	Human Rotavirus VP6-Specific Antibodies Mediate Intracellular Neutralization by Binding to a Quaternary Structure in the Transcriptional Pore. PLoS ONE, 2013, 8, e61101.	2.5	51
29	Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses. Journal of Clinical Investigation, 2013, 123, 4405-4409.	8.2	31
30	Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses. Journal of Clinical Investigation, 2013, 123, 4979-4979.	8.2	0
31	Constant Domain-regulated Antibody Catalysis*. Journal of Biological Chemistry, 2012, 287, 36096-36104.	3.4	14
32	Antigen-specific Proteolysis by Hybrid Antibodies Containing Promiscuous Proteolytic Light Chains Paired with an Antigen-binding Heavy Chain. Journal of Biological Chemistry, 2009, 284, 24622-24633.	3.4	13
33	Exceptional Amyloid β Peptide Hydrolyzing Activity of Nonphysiological Immunoglobulin Variable Domain Scaffolds. Journal of Biological Chemistry, 2008, 283, 36724-36733.	3.4	36